Table 3.

Semiquantitative analysis of antibody response to angiogenic cytokines in vaccinated patients with recurrent malignant glioma. Patients 2,3,4, 5, and 11 received bevacizumab at weeks 7,6,10,10, and 10 respectively.

Patient number	L1	DEL-1	Ang1	Ang2	HGF	PDGF	VEGF-A*	VEGF-A	PGRN
2					+		+	+++
3			+	+++	+	+		+++	+
4	++		+++	+++	+	+		+++
5	++		+++	+++	+	+++		+++	+++
6				+++	+	+
8				+	+	+	+
9				+++		+
10			+	+++	++	+++
11			++	+++	+	+	+		+

Note: +, two and one half to 5-fold increases; ++ 5- to 7-fold increases; +++, 8- and greater fold increases

^*VEGF-A before bevacizumab. Patients 2–5 had blood sampled after bevacizumab administration